Roivant Sciences Ltd at Goldman Sachs CEOs Unscripted Conference Transcript
Great. Well, thanks for coming, Matt, and thanks for everyone who's joining us both in-person and on the web stream.
So maybe, Matt, just to start, could you please just provide a brief overview of what you view as the key programs that are going to shape the Roivant story as we think about 2023?
Sure. And thanks, Corinne, for having me and thanks to the conference for having us. It's great to be here. So I appreciate it.
Yes. Look, 2023 is a pretty incredible year for us actually. So I'd say major catalysts across, let's say, 4 programs at Roivant. We have this anti-TL1A antibody RVT-3101 that we in-licensed from Pfizer just last month on which we put out top-line data from our induction study yesterday. So there's additional data coming from that program midyear, first half of the year from our [maintenance] study. We have atopic dermatitis data coming from our commercial tapinarof VTAMA cream for
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
